Morgan Stanley Maintains Overweight on Zealand Pharma, Raises Price Target to $38

Morgan Stanley maintains Zealand Pharma (NASDAQ:ZEAL) with a Overweight and raises the price target from $35 to $38.

Benzinga · 01/17/2020 13:32

Morgan Stanley maintains Zealand Pharma (NASDAQ:ZEAL) with a Overweight and raises the price target from $35 to $38.